Administration of Recombinant Human GHRH-1,44-amide for 3 Months Reduces Abdominal Visceral Fat Mass and Increases Physical Performance Measures in Postmenopausal Women
European Journal of Endocrinology - United Kingdom
doi 10.1530/eje.1.02019
Full Text
Open PDFAbstract
Available in full text
Date
November 1, 2005
Authors
Publisher
Bioscientifica